賽生藥業(06600.HK)與零氪科技簽署戰略合作協議
賽生藥業(06600.HK)公布,與零氪科技簽署戰略合作協議,雙方將進一步合力打造創新支付和數字化服務相結合的創新患者服務模式,探索新的藥品渠道流通及交付模式,推動雙方與順豐醫藥的創新藥品流通模式合作,不斷提升藥品的可及性和患者服務水平。
賽生藥業總裁兼首席執行官趙宏表示,雙方將持續優化創新患者服務模式,不斷提升高品質創新藥品的可及性,助力國家完善多層次醫療保障體系,從而更好地服務於廣大患者,更高效地推動行業創新前行。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.